Dragonfly Therapeutics
Stephen Schmitz, MD, MPH, possesses extensive experience in the field of pharmacovigilance and medical safety. Currently serving as the Vice President of Pharmacovigilance at Dragonfly Therapeutics, Inc., Stephen previously held the position of Chief Medical Officer at Ur24Technology, Inc. Additionally, Stephen has worked as Vice-President of Global Medical Safety at Kiniksa Pharmaceuticals and as Vice-President of Pharmacovigilance and Risk Management at Wave Life Sciences.
This person is not in any teams
This person is not in any offices
Dragonfly Therapeutics
1 followers
Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer.